AMPK-dependent and -independent coordination of mitochondrial function and muscle fiber type by FNIP1

Liwei Xiao1*, Jing Liu1*, Zongchao Sun1*, Yujing Yin1, Yan Mao1, Dengqiu Xu1, Lin Liu1, Zhisheng Xu1, Qiqi Guo1, Chenyun Ding1, Wanping Sun1, Likun Yang1, Zheng Zhou1, Danxia Zhou1, Tingting Fu1, Wenjing Zhou2, Yuangang Zhu2, Xiao-Wei Chen2, John Zhong Li3, Shuai Chen4, Xiaoduo Xie5, Zhenji Gan1*  

1 MOE Key Laboratory of Model Animals for Disease Study, Department of Spine Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Chemistry and Biomedicine Innovation Center (ChemBIC), Model Animal Research Center, Nanjing University Medical School, Nanjing University, Nanjing, China, 2 Institute of Molecular Medicine, Peking University, Beijing, China, 3 The Key Laboratory of Rare Metabolic Disease, Department of Biochemistry and Molecular Biology, The Key Laboratory of Human Functional Genomics of Jiangsu Province, Nanjing Medical University, Nanjing, China, 4 MOE Key Laboratory of Model Animals for Disease Study, Model Animal Research Center, Nanjing University Medical School, Nanjing University, Nanjing, China, 5 Department of Biochemistry, School of Medicine, Sun Yat-sen University, Shenzhen, China

* These authors contributed equally to this work.

Abstract

Mitochondria are essential for maintaining skeletal muscle metabolic homeostasis during adaptive response to a myriad of physiologic or pathophysiologic stresses. The mechanisms by which mitochondrial function and contractile fiber type are concordantly regulated to ensure muscle function remain poorly understood. Evidence is emerging that the Folliculin interacting protein 1 (Fnip1) is involved in skeletal muscle fiber type specification, function, and disease. In this study, Fnip1 was specifically expressed in skeletal muscle in Fnip1-transgenic (Fnip1Tg) mice. Fnip1Tg mice were crossed with Fnip1-knockout (Fnip1KO) mice to generate Fnip1TgKO mice expressing Fnip1 only in skeletal muscle but not in other tissues. Our results indicate that, in addition to the known role in type I fiber program, FNIP1 exerts control upon muscle mitochondrial oxidative program through AMPK signaling. Indeed, basal levels of FNIP1 are sufficient to inhibit AMPK but not mTORC1 activity in skeletal muscle cells. Gain-of-function and loss-of-function strategies in mice, together with assessment of primary muscle cells, demonstrated that skeletal muscle mitochondrial program is suppressed via the inhibitory actions of FNIP1 on AMPK. Surprisingly, the FNIP1 actions on type I fiber program is independent of AMPK and its downstream PGC-1α. These studies provide a vital framework for understanding the intrinsic role of FNIP1 as a crucial factor in the concerted regulation of mitochondrial function and muscle fiber type that determine muscle fitness.
Mitochondria provide an essential source of energy to drive cellular processes and the function of mitochondria is particularly important in skeletal muscle, a metabolically demanding tissue that depends critically on mitochondria, accounting for ~40% of total body mass. In this study, we discovered an essential function of adaptor protein FNIP1 in the coordinated regulation of the mitochondrial and structural programs controlling muscle fitness. Using both gain-of-function and loss-of-function strategies in mice and muscle cells, we provide clear genetic data that demonstrate FNIP1-dependent signaling is crucial for muscle mitochondrial remodeling as well as type I muscle fiber specification. We also uncover that FNIP1 exerts control upon muscle mitochondrial program through AMPK but not mTORC1 signaling. Furthermore, we demonstrate that FNIP1 acts independently of PGC-1α to regulate fiber type specification. Hence, our study emphasizes FNIP1 as a dominant factor that coordinates mitochondrial and muscle fiber type programs that govern muscle fitness.

Introduction

Mitochondria are essential organelles that serve diverse functions including bioenergetics, metabolism and signaling. Mitochondria are particularly important for maintaining metabolic homeostasis in skeletal muscle, the largest metabolic demanding tissue that undergoes extensive remodeling in response to myriad physiologic or pathophysiological stimuli. Significant evidence suggests that the function of mitochondria in skeletal muscle is compromised in the pathogenesis of many human diseases including obesity, type 2 diabetes and muscular dystrophy/atrophy [1–4]. Conversely, Exercise training is effective in counteracting the effects of many chronic diseases on mitochondrial function in skeletal muscle [4–8]. Thus, a better understanding of the molecular factors controlling mitochondrial function muscle fiber type programs could have implications for new therapeutic approaches for many human diseases associated with muscle mitochondrial defects.

Previous studies have demonstrated that the AMPK and PGC-1α are key transducers of exercise-mediated beneficial effects on muscle mitochondria. AMPK is activated by reduction of muscle ATP levels following exercise, providing a mechanism to integrate physiological exercise signals with the control of muscle mitochondrial system. AMPK was demonstrated to be essential for maintaining mitochondrial function in the skeletal muscle [9–11]. Indeed, AMPK activation in skeletal muscle is sufficient to drive a mitochondrial oxidative program in absence of any exercise [12,13]. AMPK-induced activation of muscle mitochondrial function is mediated, at least in part by PGC-1α signaling, which subsequently induces a broad array of genes involved in mitochondrial biogenesis and quality control through coactivating a number of nuclear receptors [14,15]. It is now clear that AMPK activates PGC-1α, likely through both direct phosphorylation of PGC-1α and promoting Sirt1-mediated PGC-1α activation [16,17].

Evidence is emerging that other factors may converge on AMPK and PGC-1α signaling, providing important layers of mitochondrial regulation in skeletal muscle. Folliculin interacting protein 1 (FNIP1) is an adaptor protein originally identified through its interaction with folliculin (FLCN) and AMPK [18]. Previous studies have implicated that FNIP1 influences cellular metabolic regulators such as AMPK and mTOR signaling [19–23]. However, the exact roles of FNIP1 in modulating AMPK or mTOR signaling remain unclear. Whole body deletion of Fnip1 in mice has recently been shown to increase type I muscle fiber composition and activate AMPK signaling [20], whereas it has also been shown that mice with loss of FNIP1 in
muscle actually have reduced phosphorylation of the catalytic α subunit of AMPK (Thr172) [21]. Similarly, both suppression and activation of mTOR signaling by FNIP1 have also been reported [20,21,23,24]. Collectively, the results of previous studies suggest a role for FNIP1 in muscle fiber type specification and metabolism. However, whether and how FNIP1 orchestrate muscle mitochondrial and structural programs remain unclear.

We have recently found that MyomiR miR-499 regulates muscle mitochondrial respiration through inhibiting Fnip1 [25]. Given the importance of AMPK-related signaling in mitochondrial biology and the potential role of FNIP1 in the metabolic basis of skeletal muscle function, we embarked on a study to define the precise control mechanism of FNIP1 signaling in skeletal muscle using both gain-of-function and loss-of-function strategies in mice. The markedly different muscle phenotypes of the FNIP1 deficiency mice and mice expressing FNIP1 only in skeletal muscle afforded us the unique opportunity to understand the intrinsic role of FNIP1 in the coordinated regulation of mitochondrial system and muscle fiber type that determine muscle function. Our results indicate that basal levels of FNIP1 are sufficient to simultaneously inhibit mitochondrial function and type I muscle fiber program in skeletal muscle. Using genetically engineered Fnip1 and Ampk1/a2 triple knockout mouse models and primary skeletal myotubes in culture, we demonstrated that FNIP1 exerts control upon the skeletal muscle mitochondrial oxidative program through AMPK signaling. Surprisingly, the effects of FNIP1 on type I fiber program do not dependent on the AMPK/PGC-1α cascade. These findings provide a new mechanism by which mitochondrial function and muscle fiber type are concordantly regulated and have important implications for possible therapeutic manipulation of muscle mitochondrial function muscle fiber type for maintaining muscle fitness in a variety of chronic disease states.

Results

FNIP1-dependent regulation of mitochondrial remodeling in skeletal muscle

Muscle-specific Fnip1 transgenic mice (Fnip1Tg) were established using the muscle creatine kinase promoter [26]. The Cas9 system targeting exon 6 of the Fnip1 gene was also employed to generate Fnip1 knockout mice (Fnip1KO). Fnip1Tg mice were crossed with Fnip1KO mice to generate Fnip1TgKO mice expressing Fnip1 only in skeletal muscle but not in other tissues (Fig 1A). The mouse Fnip1 transgene transcript was expressed in a skeletal muscle-specific manner, and we observed no overexpression of FNIP1 protein in the heart (S1A–S1C Fig). Fnip1Tg mice do not exhibit an overt muscle phenotype compared to nontransgenic (NTG) littermates (S1D Fig). In addition, Fnip1 overexpression does not affect muscle fiber type specification (S1E and S1F Fig). However, loss of FNIP1 resulted in a pronounced change in the color of the skeletal muscle (S2 Fig), consistent with the previous observations [20]. Gene expression analyses confirmed the efficient knock out of Fnip1 gene in Fnip1KO mice, while the mRNA expression of Fnlcp2, a close homolog of Fnip1, was increased in Fnip1KO muscle (S2C and S2D Fig). FLNCP protein levels were also increased in Fnip1KO muscle (S2D Fig). As shown in Fig 1A, skeletal muscle specific restoration of Fnip1 completely abolished the red coloration in Fnip1KO muscle (Fig 1A). Notably, Fnip1KO muscle weighted less than WT controls, and muscle weight normalized to body weight was also decreased in Fnip1KO mice compared to WT or Fnip1TgKO mice (S1 Table).

The muscle oxidative transformation is determined, largely in part, at the level of gene expression. To gain insight into the FNIP1-dependent regulation of skeletal muscle metabolism, transcriptome analysis was performed by whole-genome gene expression profiling experiments (GSE150193) in gastrocnemius (GC) muscle from both Fnip1KO and Fnip1TgKO mice.
FNIP1 coordinates mitochondrial function muscle fiber type

D

| GO cellular compartments term | Count | P value |
|-------------------------------|-------|---------|
| Mitochondrion                 | 455   | 3.30E-48 |
| Membrane                      | 1283  | 8.40E-42 |
| Mitochondrial inner membrane  | 151   | 4.40E-35 |
| Extracellular exosome         | 562   | 1.00E-28 |
| Cytosol                       | 1135  | 6.90E-22 |
| Cytosol                       | 382   | 1.40E-20 |
| Myelin sheath                 | 77    | 4.60E-19 |
| Respiratory chain             | 34    | 1.70E-14 |
| Mitochondrial respiratory chain complex I | 27 | 2.50E-11 |
| Membrane raft                 | 78    | 3.40E-11 |

E

F

G

H

I

PLOS GENETICS
Knockout of Fnip1 in skeletal muscle resulted in the up-regulation of 3115 genes and the down-regulation of 739 genes (S3 Fig), while genetic restoration of FNIP1 increased 846 genes and suppressed 265 genes (S4 Fig). Comparative analysis identified the induced expression of the major type 1 myosin Myh7 and Myh7b genes paralleled the elevated expression of miR-208b and miR-499 in Fnip1KO muscle (S3E and S3F Fig). Interestingly, the expression of the gene encoding Esrrb and Esrrg, known activators of Myh7/miR-208b and Myh7b/miR-499 was also increased in Fnip1KO muscle compared with that in WT controls (S3E Fig). The up- or down-regulated genes are highlighted in red and green, respectively, in Fig 1B. We were particularly interested in the subset of genes that were regulated only in the Fnip1KO muscle but not in Fnip1TgKO muscle. The number of genes that were regulated uniquely or shared by the two genotypes is displayed in the Venn diagram (Fig 1C). Of the 3854 genes that were regulated in the Fnip1KO muscle, 3423 were uniquely regulated compared to the Fnip1TgKO muscle. In addition, 1111 genes were regulated in Fnip1TgKO muscle (Figs 1G and S4A). Gene ontology (GO) analysis revealed that the primary Fnip1-regulated genes were mitochondrial-related genes (Fig 1D). A broad array of genes involved in mitochondria oxidative program was regulated in Fnip1KO muscle in an Fnip1-dependent manner (Figs 1D and S3C and S2 Table).

Together, the transcriptional profiling results indicate that a significant subset of Fnip1 target genes in skeletal muscle were those involved in mitochondrial program.

Validation studies confirmed that the expression of proteins involved in mitochondrial fusion and fission, including OPA1, MFN1, MFN2 and DRP1, was significantly up-regulated in the muscle of the Fnip1KO mice but reduced in Fnip1TgKO muscle (Figs 1E and S5A). These results suggested that FNIP1 are also critical for mitochondrial dynamics and quality control in skeletal muscle. We next analyzed mitochondrial morphology in wild-type (WT), Fnip1KO and Fnip1TgKO muscle. Mitochondrial volume density, size, and ultrastructure were assessed by electron microscopy (EM) in the intermyofibrillar (IMF) compartments of the tibialis anterior (TA) muscle fibers of all three genotypes (Fig 1F). EM analyses showed a striking increase of mitochondrial area per muscle fiber area in IMF regions in the Fnip1KO mice compared with that in WT controls (Figs 1F and 1G). Notably, the WT and Fnip1TgKO mice have an ordered array of small IMF mitochondria along the Z-lines of the sarcomeres, whereas the Fnip1KO mice have more numerous and often significantly larger mitochondria, which displaced the myofibrils (Fig 1F). Consistent with the EM data, mitochondrial DNA levels were induced in parallel with the observed morphology changes among the genotypes (Fig 1H). Together, these results implicate FNIP1 in both muscle mitochondrial biogenesis and quality control programs.

Mitochondrial respiration rates were determined in muscle of all three genotypes using pyruvate or succinate as substrates (Fig 1I). Consistent with the morphology changes, both
Pyruvate- and succinate-driven mitochondrial respiration rates were markedly induced in Fnip1\(^{KO}\) muscles compared to the WT controls (Figs 1I and S5B). Mitochondrial respiration rates from Fnip1\(^{TgKO}\) muscles were reduced to a level similar to WT controls (Fig 1I). Together, these data strongly demonstrate that FNIP1 is a negative regulator for skeletal muscle mitochondrial remodeling.

**FNIP1-dependent muscle oxidative fiber type transformation**

The correction of muscle mitochondrial phenotypes in Fnip1\(^{TgKO}\) mice afforded us the opportunity to use a comparative molecular profiling strategy to identify FNIP1-dependent regulatory pathway involved in the control of muscle metabolism. Consistent with the FNIP1-dependent regulation of mitochondrial biogenesis, immunoblotting analyses confirmed the increase of complex I (NDUF8), complex III (UQCRC2), complex IV (COX4), and ATP synthase (ATP5A) proteins in Fnip1\(^{KO}\) but not in Fnip1\(^{TgKO}\) muscles (Figs 2A and S3C). The expression of myoglobin and cytochrome c, muscle oxidative metabolism biomarkers and known PGC-1\(\alpha\) targets, was induced in Fnip1\(^{KO}\) mice but completely reversed by Fnip1 restoration (Figs 2B and S5C and S5D). The conversion between lactate and pyruvate in skeletal muscle is regulated by the LDHB/LDHA isoenzyme ratio, with LDHB favors the reaction that convert lactate to pyruvate and LDHA favors the reverse reaction to produce lactate [27,28]. The Ldhb gene expression was increased in Fnip1\(^{KO}\) muscle but markedly reduced in Fnip1\(^{TgKO}\) muscle (Fig 2C). The expected LDH isoenzyme activity shifts were confirmed by activity gel studies (Figs 2D and S5E). Moreover, muscle specific restoration of Fnip1 reversed the reduction of blood lactate levels in Fnip1\(^{KO}\) mice (Fig 2E).

Mitochondrial system is tightly coupled to muscle contractile fiber type. To further evaluate the effect of Fnip1 on muscle oxidative transformation, we performed histochemical staining for succinate dehydrogenase (SDH) and myosin heavy chain (MHC) 1, which are hallmarks for oxidative metabolism, respectively [29]. As expected, the SDH enzymatic activities were higher in the GC muscle of Fnip1\(^{KO}\) mice compared to WT controls or Fnip1\(^{TgKO}\) mice (Fig 2F and 2G). MHC1 immunostaining demonstrated that Fnip1 restoration reversed the induction of type I muscle fibers in both soleus and GC muscles of Fnip1\(^{KO}\) mice (Figs 2F and 2G and S6A). These results further demonstrate a FNIP1-dependent muscle oxidative transformation.

**FNIP1 regulates AMPK but not mTORC1 in skeletal muscle cells**

Recently, FNIP1 was shown to influence both AMPK and mTORC1 signaling in multiple cells [19–23], but the precise role of FNIP1 is uncertain. We thus examined the AMPK and mTOR signaling in the muscles of Fnip1\(^{KO}\) and Fnip1\(^{TgKO}\) mice. As shown in Fig 3A and 3B, Western blot confirmed that levels of phosphorylated AMPK\(\alpha\) (Thr172) were higher in Fnip1\(^{KO}\) but dramatically reduced in Fnip1\(^{TgKO}\) muscle (Fig 3A and 3B). Whereas levels of phosphorylated mTOR as well as downstream products of mTORC1 activation, including phosphorylated ribosomal S6 protein kinase (p-S6K), ribosomal S6 protein (p-S6) and EIF4E-binding protein 1 (p-4EBP1), were not different in Fnip1\(^{KO}\) muscles compared with Fnip1\(^{TgKO}\) muscles (Figs 3A and 3B and S6B and S6C), suggesting that FNIP1 effect on mitochondrial oxidative program without changes in mTORC1 signaling in skeletal muscle. To further investigate the findings in a cell-autonomous setting, primary muscle myoblasts were isolated from GC muscles of Fnip1\(^{KO}\) and WT mice, and then induced to differentiation for 3 days. As expected, Fnip1\(^{KO}\) myotubes showed a significant increase in phosphorylation of AMPK\(\alpha\), and there are no changes in mTORC1 signaling in WT and Fnip1\(^{KO}\) myotubes (Fig 3C and 3D). Subunits of
FNIP1 coordinates mitochondrial function muscle fiber type

A

B

C

D

E

F

G
the respiratory chain complexes and the ATP synthase were induced by Fnip1KO in myotubes (Fig 3E).

To further determine the effects of FNIP1 on muscle cell mitochondrial function, oxygen consumption rates (OCR) were measured in primary myotubes. As shown in Fig 3F, knocking out of Fnip1 significantly stimulated OCR in the presence of the uncoupler FCCP (Fig 3F). We also determined the extracellular acidification rate (ECAR) (a measure of glycolysis) along with OCR in these cells. Fnip1KO significantly increased OCR/ECAR ratio in the presence of pyruvate, indicative a shift toward more oxidative phosphorylation for cellular energy production (Fig 3G). Taken together, these results demonstrate that Fnip1 deficiency activates AMPK and mitochondrial oxidative program in skeletal muscle cells in a cell-autonomous manner.

**FNIP1 regulates muscle mitochondrial oxidative program through AMPK**

We next addressed whether FNIP1 mediates its effect on skeletal muscle mitochondrial oxidative program through activation of AMPK. We bred Fnip1KO mice with muscle-specific Ampkα1/α2 double KO mice (Ampkα1/α2f/f/Mf5-Cre) to generate Fnip1KO, Ampkα1/α2f/f/Myf5-Cre (TKO) mice, in which Ampkα1/α2 genes are disrupted in muscle in Fnip1KO background (Fig 4A). Muscle specific disruption of Ampkα1/α2 resulted in marked reduction of pyruvate-driven mitochondrial respiration rates in the EDL muscle of Fnip1KO mice (Fig 4B and 4C). Moreover, Fnip1 deficiency-mediated induction of mitochondrial dynamics proteins OPAL1, MFN1 and MFN2, as well as oxidative biomarker cytochrome c was significantly reduced in the absence of Ampkα1/α2 (Figs 4D and 4E and 5A). Furthermore, muscle specific disruption of Ampkα1/α2 also resulted in decreased LDHb/LDHa ratio in Fnip1KO muscle (Fig 4F). We also generated a second skeletal muscle-specific Ampkα1/α2-knockout mouse lines (Ampkα1/α2f/f/MCK-Cre) using the muscle creatine kinase promoter-driven Cre [30]. As observed in TKO muscle, mitochondrial program was significantly decreased in Fnip1KO, Ampkα1/α2f/f/MCK-Cre, mice, based on analysis of mitochondrial respiratory chain complexes and oxidative biomarkers in muscle (Fig 4G and 4H). Together with the results obtained from the TKO mice, these data strongly suggest that AMPK is required for the FNIP1 deficiency-mediated increase in mitochondrial oxidative program in skeletal muscle.

We also took advantage of primary muscle cell cultures derived from Fnip1KO and TKO mice to further assess the AMPK-dependent regulation of mitochondrial program by FNIP1. Western blot confirmed that disruption of Ampkα1/α2 completely abolish AMPK activation without affecting mTORC1 signaling in TKO myotubes (Fig 5A). We show that knocking out Ampkα1/α2 blunted the effect of Fnip1KO on the expression of the mitochondrial respiratory chain complexes and the ATP synthase, as well as the oxidative biomarkers myoglobin and cytochrome c (Figs 5B and 5C). Moreover, Ampkα1/α2 ablation also resulted in marked reduction of mitochondrial dynamic gene expression in Fnip1KO myotubes (Fig 5C).
Fig 3. FNIP1 inhibits muscle AMPK pathway and mitochondrial oxidative program in a cell-autonomous manner. (A) Representative immunoblot analysis of WV muscle lysates for mice of the indicated genotype using the indicated antibodies. (B) Quantification of the p-AMPKα (Thr172)/AMPKα, p-mTOR (Ser2448)/mTOR, p-mTOR (Ser2481)/mTOR signal ratios were normalized (= 1.0) to the WT controls. n = 3–6 mice per group. (C-E) Primary skeletal muscle myoblasts were isolated from GC muscles of Fnip1ko and WT mice, and then induced to differentiation for 3 days. (C) Immunoblot analysis of myotube extracts using the indicated antibodies.
Averaged p-AMPKα (Thr172)/AMPKα ratios were shown after normalization to the value of WT controls. n = 5 independent experiments. (D) Representative immunoblot analysis of myotube extracts using the indicated antibodies. n = 3 independent experiments. (E) Immunoblot analysis of myotube extracts using the indicated antibodies. Averaged NDUFB8/Tubulin, UQCRC2/Tubulin, COX4/Tubulin and ATP5A/Tubulin ratios were shown after normalization to the value of WT controls. n = 4 independent experiments. (F) Oxygen consumption rates (OCR) in primary myotubes harvested from indicated mice. Basal OCR was first measured, followed by administration of 10 mM sodium pyruvate, and 2 μM oligomycin (to inhibit ATP synthase), uncoupler FCCP (2 μM), or rotenone/antimycin (Rot/A; 1 μM) as indicated. n = 3 separate experiments done with 5–7 biological replicates. Data were analyzed by two-way ANOVA and Bonferroni post-hoc test. (followed by administration of 10 mM sodium pyruvate, and 2

Furthermore, mitotracker fluorescence analyses confirmed an increase in the mitochondrial mass in Fnip1KO myotubes compared to WT or TKO myotubes (S7C and S7D Fig). We also demonstrate that knocking out Ampka1/a2 blunted the effect of Fnip1KO on mitochondrial OCR (Fig 5D and 5E). Taken together, these results demonstrate that the FNIP1/AMPK pathway regulates mitochondrial oxidative program in myotubes in a cell-autonomous manner.

AMPK-independent regulation of muscle fiber type switching by FNIP1

We also investigate whether FNIP1 mediates its effect on muscle fiber type transformation through AMPK. Surprisingly, no significant changes in MHC1 immunofluorescence was observed in the soleus muscle of TKO mice compared to Fnip1KO mice (Fnip1KO, 83.3 ± 6.2% vs. TKO, 82.2 ± 6.4%, n = 5–6 mice per group, p = 0.75) (Fig 6A and 6B). Similar observations were made in multiple muscle types of the TKO mice, in which the number of slow-twitch type I fibers was increased by Fnip1KO but not affected by disruption of Ampka1/a2 in GC, and EDL muscle (Fig 6A and 6B). As observed in TKO muscle, no changes in type I fiber proportion was also observed in the GC muscle of Fnip1KO mice compared to Fnip1KO, Ampka1/a2KO mKO (DKO) mice (Fig 6C). Consistent with the fiber typing results, gene expression studies demonstrate that the expression of the gene encoding the major slow-twitch type I myosin isoform MHC1 (Myh7 gene) and slow-twitch troponin genes was increased in both GC and soleus muscles of Fnip1KO mice but not affected by Ampka1/a2 disruption (Figs 6D and 8). These data suggest that AMPK is dispensable for the FNIP1-mediated control of muscle mitochondrial system, but not fiber-type specification.

Previous studies have established that AMPK-induced activation of muscle mitochondrial function is mediated, at least in part by PGC-1α signaling [16,17]. To further confirm the role of AMPK signaling in FNIP1-mediated skeletal muscle mitochondrial reprogramming, we bred Fnip1KO mice with muscle-specific PGC-1α KO (PGC-1α mKO) mice to generate Fnip1KO, PGC-1αKO mKO (DKO) mice, in which the PGC-1α gene is disrupted in muscle in Fnip1KO background (Fig 7A). Western blotting confirmed that the induced expression of PGC-1α protein was completely abolished in the DKO muscle (Fig 7B). As shown in Fig 7C, muscle specific disruption of PGC-1α resulted in marked reduction of pyruvate-driven mitochondrial respiration rates in the EDL muscle of Fnip1KO mice (Fig 7C). FNIP1 deficiency-mediated induction of mitochondrial genes (NDUFB8, ATP5A, and cytochrome c) was significantly reduced in the absence of PGC-1α (Figs 7D and S9). Moreover, PGC-1α ablation also resulted in marked reduction of mitochondrial dynamic gene expression in Fnip1KO muscle (Fig 7E). Furthermore, muscle specific disruption of PGC-1α also reversed LDHB/LDHA isoenzyme ratio in Fnip1KO muscle (Fig 7F). Together, these results further establish the importance of AMPK/PGC-1α cascade in the FNIP1 deficiency-mediated activation of mitochondrial oxidative program in skeletal muscle.

SDH histochemical staining revealed that muscle specific disruption of PGC-1α resulted in marked reduction of mitochondrial oxidative activity in the GC muscle of Fnip1KO mice (Fig 7G). Interestingly, however, no significant changes in MHC1 immunofluorescence was
Fig 4. FNIP1 regulates muscle mitochondrial oxidative programs through AMPK. (A) Schematic showing the creation of Fnip1<sup>KO</sup>, Ampka1/2<sup>fl/fl/Myf5-Cre</sup> (TKO) mice. 

(B) Representative immunoblot analysis performed with EDL muscle total protein extracts prepared from the indicated mice using p-AMPKα (Thr172), AMPKα, FNIP1 and α-Tubulin (control) antibodies. n = 6 mice per group. 

(C) Mitochondrial respiration rates were determined from EDL muscle of the indicated genotypes using pyruvate as a substrate. Pyruvate/malate (Py/M)-stimulated, ADP-dependent respiration and oligomycin-induced (Oligo) are shown. n = 9–12 mice per group.
observed in both soleus and GC muscle of DKO mice compared to *Fnip1* KO mice (Fig 7H and 7I). These results demonstrate that PGC-1α is dispensable for the FNIP1 deficiency-mediated control of type I muscle fiber formation, which are consistent with AMPK-independent regulation of muscle fiber type specification by FNIP1.

**Discussion**

Skeletal muscle comprises ~40% of human body mass and is a key determinant of whole body energy metabolism. Mitochondria are undoubtedly critical for muscle functions. The molecular mechanisms involved in the coordinated regulation of the mitochondrial and structural determinants of muscle function are of particular interest because of their relevance to many human disorders, including obesity, type 2 diabetes and muscular diseases [1–4]. In this study, we identify FNIP1 as a crucial factor that dually regulates skeletal muscle mitochondrial and structural programs through both AMPK-dependent and -independent mechanisms. Our findings implicate the FNIP1 signaling serves as a dominant pathway that coordinates mitochondrial system and skeletal muscle fiber type that determine muscle fitness.

Our findings that muscle FNIP1 orchestrates mitochondrial function and type I muscle fiber programs through both AMPK-dependent and -independent mechanisms revealed an important intrinsic role of FNIP1 in skeletal muscle metabolic control, and elucidated a mechanism by which mitochondrial function and muscle fiber type are concordantly regulated. Previous study using whole body knockout mice has provided a clue that FNIP1 is involved in skeletal muscle metabolic control, and disease [20]. However, whole body deletion of *Fnip1* also leads to multiple nonmuscle system derangements including immune cell development defect, cardiomyopathy, and renal cyst formation [19,20,22,31,32]. It is unclear whether the muscle changes are autonomous to muscle cells or secondary effects driven by deletion of *Fnip1* in nonmuscle tissues. Moreover, although previous studies have implicated that FNIP1 could influence both AMPK and mTORC1 signaling in multiple cell types [19–23], reports on the effects of FNIP1 on AMPK and mTORC1 signaling have been inconsistent and, thus, less conclusive [19–24]. Therefore, the intrinsic physiological role of FNIP1 in skeletal muscle remains unclear. In this study, we took advantage of the *Fnip1* KO and *Fnip1* TgKO mice expressing *Fnip1* only in skeletal muscle but not in other tissues to explore the detailed insights of FNIP1 actions in skeletal muscle. Gain-of-function and loss-of-function studies in mice, together with assessment of primary skeletal myotubes in culture, afforded us the unique opportunity to define the intrinsic role of FNIP1 in skeletal muscle. Our strong genetic data led to the following surprising conclusions: 1) basal levels of FNIP1 are sufficient to function as a “brake” to simultaneously inhibit mitochondrial and type I fiber programs in skeletal muscle, while muscle-specific *Fnip1* transgenic mice (*Fnip1* Tg) appeared normal on inspection, and did not exhibit a muscle phenotype compared to NTG littermates; 2) FNIP1 in fact cell-autonomously regulates AMPK but not mTORC1 signaling in skeletal muscle cells, thus shed light on the inconsistencies in previous data; 3) FNIP1 regulates muscle mitochondrial oxidative program through AMPK, these findings are recapitulated in skeletal muscle cell culture and, thus, are cell autonomous; 4) FNIP1 regulates type I fiber program independent of...
Fig 5. FNIP1 regulates muscle mitochondrial oxidative programs through AMPK in a cell-autonomous manner. (A–C) Primary myoblasts were isolated from GC muscles of indicated mice, and then induced to differentiation for 3 days. (A) Representative immunoblot analysis of myotube extracts using the indicated antibodies. n = 3–4 independent experiments. (B, C) Immunoblot analysis of myotube extracts using the indicated antibodies. Averaged NDUFB8/Tubulin, UQCRC2/Tubulin, COX4/Tubulin, ATP5A/Tubulin, Myoglobin, Cyt C, FNIP1, OPA1/Tubulin, MFN1/Tubulin and MFN2/Tubulin ratios were shown after normalization to the value of WT controls. n = 3–5 independent experiments. (D) Oxygen consumption rates (OCR) in primary myotubes harvested from indicated mice. Basal OCR was first measured, followed by administration of 10 mM sodium pyruvate, and 2 μM oligomycin (to inhibit ATP synthase), uncoupler FCCP (2 μM), or rotenone/antimycin (Rot/A; 1 μM) as indicated. n = 3 separate experiments done with 5–7 biological replicates. Data were analyzed by two-way ANOVA and Bonferroni post-hoc test. (E) OCR/ECAR ratio using pyruvate as substrate indicates a shift in cell energy production to oxidative phosphorylation. n = 3 separate experiments done with 5–7 biological replicates. Values represent mean ± SD, * P < 0.05 vs. WT controls, # P < 0.05 vs. Fnip1KO.
FNIP1 coordinates mitochondrial function muscle fiber type

**A**

|         | Soleus | GC       | EDL       |
|---------|---------|----------|-----------|
| WT      | ![Image](WT_Soleus.png) | ![Image](WT_GC.png) | ![Image](WT_EDL.png) |
| KO      | ![Image](KO_Soleus.png)  | ![Image](KO_GC.png)  | ![Image](KO_EDL.png)  |
| TKO     | ![Image](TKO_Soleus.png) | ![Image](TKO_GC.png) | ![Image](TKO_EDL.png) |

**B**

- **Soleus** Type I fiber (%)
- **Medial GC** Type I fiber/section
- **EDL** Type I fiber/section

**C**

- **WT**
- **KO**
- **KO, Aompka1/2ff/MCK-Cre**

**D**

- **MHC**
- **Slow-twitch**
- **Fast-twitch**
AMPK/PGC-1α, mitochondrial function and muscle fiber type are indeed controlled by distinct signaling pathways. Therefore, we have genetically established a pivotal intrinsic role for FNIP1 in orchestrating mitochondrial function and type I muscle fiber, as well as its epistatic relationship with AMPK and PGC-1α in driving type I muscle fiber determination in skeletal muscle.

Our data strongly suggest that the major effect of FNIP1 on muscle mitochondrial system might be mediated through inhibition of AMPK signaling. First, we found that AMPK but not mTORC1 was activated in Fnip1KO but reduced to basal levels in Fnip1TgKO muscle. Second, two independent triple knockout Ampkα1α2 and Fnip1 mice experiments demonstrated that AMPK is required for the Fnip1 deficiency-mediated increase in mitochondrial oxidative program in skeletal muscle. Third, we confirmed that FNIP1 negatively regulates muscle cell mitochondrial program through inhibiting AMPK in a cell-autonomous setting. Notably, FLCN has also been shown to act through AMPK/PGC-1α function to handle various types of stress conditions in C. elegans and mammalian models [33–36], which further emphasizes the importance of AMPK/PGC-1α in mediating FNIP1/FLCN actions. However, a surprising finding of our study was dissociation between mitochondrial function and type I fiber program in TKO and DKO muscle mice, and we concluded that FNIP1-dependent type I muscle fiber program does not require the AMPK/PGC-1α signaling based on our multiple genetic mouse line studies. We show that disruption of Ampkα1α2 in Fnip1KO muscle resulted in significantly reduced mitochondrial function but, surprisingly, have no effect on Fnip1 deficiency-mediated type I muscle fiber switching in multiple muscle types. Consistent with TKO and Fnip1KO, Ampkα1α2KO/MCK-Cre mice, we found that FNIP1 is involved in type I muscle fiber determination independently from PGC-1α. It is possible independent pathways are activated in parallel with AMPK/PGC-1α signaling to regulate type I muscle fiber determination in Fnip1KO muscle. Previous studies have identified multiple transcriptional signaling, such as calcineurin/NFAT, HDAC/MEF2, nuclear receptor/miRNA axis, and HSF1 in the regulation of type I muscle fiber specification [25,37–41]. Interestingly, we found that the ERRs/miRNA axis is activated, whereas the expression of the genes encoding calcineurin, NFATs, MEF2s and HSF1 was not increased in Fnip1KO muscle. We have previously reported that Fnip1 is a direct target of miR-499, acting downstream of the ERRs/miR-499 axis [25,40], thereby suggesting a feedback loop whereby the FNIP1 pathways described here acts independently of PGC-1α to regulate fiber type specification.

We found that Fnip1 deficiency in skeletal muscle triggers a robust mitochondrial beneficial remodeling and glycolytic-to-oxidative muscle fiber transformation in the absence of exercise. Thus our findings reveal an exercise-independent FNIP1 pathway that coordinately regulates the mitochondrial and structural determinants of muscle fitness. Whereas we found that FNIP1 simultaneously regulates mitochondrial oxidative program and type I muscle fiber type in multiple muscle types across a range of fiber type proportions and oxidative capacity, our data also suggest that FNIP1 exerts a different control effect on MHC2a and MHC2x expression in different muscle types. This could reflect the intrinsic differences between muscles at the baseline that affect the adaptive range of MHC transformations [29]. Notably, the mitochondria in the skeletal muscle of Fnip1KO mice were more numerous and often significantly
larger than the WT controls. In some muscle regions, the marked mitochondrial proliferation appeared to have replaced the myofibrillar contractile apparatus. In addition, our data also suggested a role of muscle FNIP1 in controlling body weight and muscle mass. It is possible that the difference in muscle size could reflect the muscle fiber type switching. It is also possible that FNIP1 directly regulates the dynamic balance between protein synthesis and degradation that determine muscle mass. Future studies will be necessary to further delineate the FNIP1 signaling in regulating muscle atrophy.

Whereas our results provide significant evidence that Fnip1 deficiency triggers muscle mitochondrial function through activating AMPK, the mechanism whereby AMPK is activated in Fnip1KO muscle was not fully delineated in this study. Evidence has emerged that the lysosomal v-ATPase-ragulator complex is critical for AMPK activation [42]. Given that FNIP1 is known to be recruited to lysosomes [24,43], it is possible that FNIP1 could serve as an adaptor protein to interact with the AMPK activation complex at the surface of lysosomes, thus modulating the activation of AMPK. In addition, FNIP1 was recently shown to act as co-chaperone of Hsp90 to control protein stability [44]. Whether such mechanisms are relevant to the actions of FNIP1 on AMPK remains to be determined. In addition, our data suggest that FNIP1 could not only regulate mitochondria biogenesis, but also regulate mitochondrial quality. Consistent with this notion, recent study also showed that FNIP1 regulate mitochondrial redox homeostasis [45].

In summary, our study illustrates a previously unrecognized intrinsic role of FNIP1 that coordinately regulates mitochondrial function and muscle fiber type that govern muscle fitness. Given that many disease states are associated with diminished mitochondrial function and reduced numbers of slow muscle fibers. The regulatory network described here shows promise for the identification of therapeutic targets aimed at coordinately increasing mitochondrial function and muscle type I fibers.

Materials and methods

Ethics statement

All animal studies were conducted in strict accordance with the institutional guidelines for the humane treatment of animals and were approved by the IACUC committees at the Model Animal Research Center (MARC) of Nanjing University.

Animal studies

WT C57BL/6j mice were from GemPharmatech Co., Ltd (Jiangsu, China). To generate mice with muscle-specific Fnip1 overexpression (Fnip1Tg), a cDNA encoding the mouse Fnip1 gene
was cloned into the EcoRV site downstream of the mouse Mck gene promoter (kind gift of E. N. Olson, University of Texas Southwestern). The transgene was linearized with XhoI and SacII digestion and microinjected into C57BL/6J embryos by the transgenic mouse facility at the Model Animal Research Center of Nanjing University. Transgenic mice were identified by PCR amplification of a 534-bp product using primers specific for Fnip1 (5'-TTTCCAACC TGCCTCATCCACTCTCTCA) and the human growth hormone poly (A) component of the MCK construct (5'-ATTGCAGTG AGCCAAGATTGTGCCACTGCA). Fnip1KO mice were generated by the transgenic mouse facility at the Model Animal Research Center of Nanjing University. Briefly, the Cas9 system targeting the exon 6 of the C57BL/6J mice Fnip1 gene was applied. The Cas9 protein and the sgRNAs were microinjected into the zygotes, and the injected zygotes were transplanted into the oviduct of pseudopregnant mothers. The sequences of sgRNA oligos are listed in S3 Table. Fnip1Tg mice were crossed with Fnip1KO mice to generate Fnip1TgKO mice expressing Fnip1 only in skeletal muscle but not in other tissues. Generation of Ampkα1/α2f/f mice has been described elsewhere [46]. To generate mice with a muscle-specific disruption of the Ampkα1/α2 alleles in Fnip1KO mice, Ampkα1/α2f/f mice were crossed with mice expressing Cre under control of the myogenic factor 5 (Myf5) promoter (Jackson Laboratory, stock no. 010529) or the muscle creatine kinase (Mck) promoter (Jackson Laboratory, stock no. 006475) to achieve muscle specific deletion of the Ampkα1/α2 alleles in PGC-1α KO mice. PGC-1α f/f mCK-Cre mice (herein named DKO) were then crossed with Fnip1KO mice to obtain Fnip1KO, PGC-1α f/f/MCK-Cre mice. Mitochondrial respiration rates were measured in saponin-permeablized extensor digital longus and plantaris muscle fibers with pyruvate or succinate as substrates as described previously [25,28,47]. In brief, the muscle fibers were separated and transferred to BIOPS buffer (7.23 mM K$_2$EGTA, 2.77 mM Ca$_2$EGTA, 20 mM imidazole, 20 mM taurine, 50 mM potassium 2-[N-morpholino]-ethanesulfonic acid, 0.5 mM dithiothreitol, 6.56 mM MgCl$_2$, 5.7 mM ATP, and 14.3 mM phosphocreatine [PCr], pH 7.1). The muscle fibers bundles were then permeabilized with 50 μg/ml saponin in BIOPS solution. Measurement of oxygen consumption in permeabilized muscle fibers was performed in buffer Z (105 mM potassium 2-[N-morpholino]-ethanesulfonic acid, 30 mM KCl, 10 mM KH$_2$PO$_4$, 5 mM MgCl$_2$, 5 mg/ml BSA, 1 mM EGTA, pH 7.4) at 37°C and in the oxygen concentration range 220–150 nmol O$_2$/ml in the respiration chambers of an Oxygraph 2K (Oroboros Inc., Innsbruck, Austria). Following measurement of basal, pyruvate (10 mM)/malate (5 mM) or succinate (5 mM)/rotenone (10 μM) respiration, maximal (ADP-stimulated) respiration was determined by exposing the mitochondria to 4 mM ADP. Uncoupled respiration was evaluated following addition of oligomycin (1 μg/mL). Respiration rates were determined and normalized to tissue weight using Datlab 5 software (Oroboros Inc., Innsbruck, Austria), the data were expressed as “pmol O$_2$ s$^{-1}$ mg wet weight$^{-1}$”.

**Mitochondrial respiration studies**

Mitochondrial respiration rates were measured in saponin-permeablized extensor digital longus and plantaris muscle fibers with pyruvate or succinate as substrates as described previously [25,28,47]. In brief, the muscle fibers were separated and transferred to BIOPS buffer (7.23 mM K$_2$EGTA, 2.77 mM Ca$_2$EGTA, 20 mM imidazole, 20 mM taurine, 50 mM potassium 2-[N-morpholino]-ethanesulfonic acid, 0.5 mM dithiothreitol, 6.56 mM MgCl$_2$, 5.7 mM ATP, and 14.3 mM phosphocreatine [PCr], pH 7.1). The muscle fibers bundles were then permeabilized with 50 μg/ml saponin in BIOPS solution. Measurement of oxygen consumption in permeabilized muscle fibers was performed in buffer Z (105 mM potassium 2-[N-morpholino]-ethanesulfonic acid, 30 mM KCl, 10 mM KH$_2$PO$_4$, 5 mM MgCl$_2$, 5 mg/ml BSA, 1 mM EGTA, pH 7.4) at 37°C and in the oxygen concentration range 220–150 nmol O$_2$/ml in the respiration chambers of an Oxygraph 2K (Oroboros Inc., Innsbruck, Austria). Following measurement of basal, pyruvate (10 mM)/malate (5 mM) or succinate (5 mM)/rotenone (10 μM) respiration, maximal (ADP-stimulated) respiration was determined by exposing the mitochondria to 4 mM ADP. Uncoupled respiration was evaluated following addition of oligomycin (1 μg/mL). Respiration rates were determined and normalized to tissue weight using Datlab 5 software (Oroboros Inc., Innsbruck, Austria), the data were expressed as “pmol O$_2$ s$^{-1}$ mg wet weight$^{-1}$”.

**Oxygen consumption measurements**

Cellular oxygen consumption rates (OCR) and extracellular acidification rates (ECAR) were measured using the XF24 analyzer (Seahorse Bioscience Inc.) per the manufacturer’s protocol...
as described previously [25,28,47]. The basal OCR was first measured in XF Assay Media without sodium pyruvate, followed by administration of 10 mM sodium pyruvate. Uncoupled respiration was evaluated following the addition of oligomycin (2 μM) to inhibit ATP synthase, by addition of the uncoupler FCCP (2 μM), and then followed by the addition of rotenone/antimycin (1 μM). Immediately after measurement, total protein levels were measured with the Micro BCA Protein Assay Kit (Thermo scientific) for data correction.

**Histologic analyses**

Muscle tissue was frozen in isopentane that had been cooled in liquid nitrogen. Notably, the gastrocnemius (GC) and plantaris of each mouse were dissected as a whole. 10 μm-thick serial GC muscles cross-sections were cut from the knee cut side in a Leica CM1850 cryostat at -20˚C and mounted on positively charged glass slides. Transverse sections collected from the widest part (mid-belly) of the GC muscle were used for histological comparison to keep consistent between different mice. SDH and immunofluorescence (IF) stains were conducted as previously described [25,28,47]. For IF stains, the muscle fibers were stained with antibodies directed against MHC1 (BA-D5, #AB 2235587) or MHC2b (BF-F3, #AB 2266724). Briefly, slides were fixed in ice-cold 4% PFA for 5 min, and permeabilized with ice-cold 0.5% Triton X-100-PBS for 10 min. These sections were then blocked using 5% normal goat serum (NGS)-PBS for 30 min at room temperature, followed by incubation with anti-MHC2b antibody at 4˚C overnight. Three consecutive washes with PBS for 5 min each were followed by sequential incubation with goat anti-mouse IgM Alexa 568 secondary antibody (Invitrogen A21043) for 1 hour at room temperature. Muscle sections were then washed three times with PBS for 5 min each, fixed in ice-cold 4% PFA for 2 min, washed with PBS for 5 min, followed by incubation with anti-MHC1 antibody for 3 hours at room temperature. Washed three times with PBS for 5 min each, followed by incubation with goat anti-mouse IgG Alexa 488 secondary antibody (Invitrogen A11001) for 1 hour at room temperature. The staining images were captured under the confocal microscope. Quantification of histological staining was performed in a blinded manner with Image-Pro Plus software. For type I fiber and SDH staining quantification in GC muscle, data were presented as number of type I fibers per medial head of GC or percentage of positive SDH staining myofibers per medial head of GC to keep consistent between different mice.

**RNA-Seq studies**

Transcriptomics analyses were performed using RNA-sequencing as described previously [48,49]. Total RNA was isolated from the entire gastrocnemius muscle of 8-week-old male Fnip1KO, Fnip1TgKO and WT control mice using RNAiso Plus (Takara Bio). RNA-seq using Illumina HiSeq 4000 was performed by Beijing Novogene Bioinformatics Technology Co., Ltd. Two independent samples per group were analyzed. Paired-end, 150 nt reads were obtained from the same sequencing lane. Transcriptome sequencing libraries averaged 39 million paired reads per sample, with 87.1% alignment to the mouse genome (UCSC mm10). The sequencing reads were then aligned to the UCSC mm10 genome assembly using TopHat 2.0.14 with the default parameters. Fragments Per Kb of exon per Million mapped reads (FPKM) were calculated using Cufflinks 2.2.1. The criteria for a regulated gene were a fold change greater than 1.5 (either direction) and a significant P-value (< 0.05) versus WT. For pathway analysis, the filtered data sets were uploaded into DAVID Bioinformatics Resources 6.8 to review the bio pathways using the Functional Categories database. The GO analysis was used to interpret data, and the regulated terms were ranked by P-value. The heat-map analysis of regulated genes was generated by using R software (Version 3.3.2) and ggplot2/gplots.
package. The RNA-seq data have been deposited in the NCBI Gene Expression Omnibus and are accessible through GEO Series accession number GSE150193.

**RNA analyses**

Quantitative RT-PCR was performed as described previously [47,48]. Briefly, total RNA was extracted from entire gastrocnemius or soleus muscle using RNAiso Plus (Takara Bio). The purified RNA samples were then reverse transcribed using the PrimeScript RT Reagent Kit with gDNA Eraser (Takara Bio). Real-time quantitative RT-PCR was performed using the ABI Prism Step-One system with Reagent Kit from Takara Bio. Specific oligonucleotide primers for target gene sequences are listed in S4 Table. Arbitrary units of target mRNA were corrected to the expression of 36b4.

**Transmission electron microscopy**

Mice were euthanized and perfused with sodium phosphate buffer (PB, 100mM, pH7.4) and pre-fixed solution (2.5% (vol/vol) glutaraldehyde, 1% paraformaldehyde in PB). Tibialis anterior (TA) muscle was dissected, cut into small pieces and fixed in the same pre-fixed solution overnight at 4˚C. After rinsing with PB, tissues were immersed in 0.2 M imidazole in PB for 15 minutes, and then post-fixed with 1% osmium tetraoxide in PB. After rinsing with high-purity water, the samples were stained with 1% aqueous lead at 4˚C overnight. Gradient dehydration was accomplished by incrementing the concentration of acetone and embedded in epoxy resin (60˚C for 24 h). Samples were sectioned using Leica EM UC7 and placed on copper grids. Images were taken on a FEI Tecnai G2 20 Twin electron microscope equipped with an Eagle 4k CCD digital camera (FEI; USA) in a double-blind manner.

**Mitochondrial DNA analyses**

Genomic/mitochondrial DNA was measured as described previously [25]. Mitochondrial DNA content was determined by SYBR Green analysis (Takara Bio). The levels of NADH dehydrogenase subunit 1 (mitochondrial DNA) were normalized to the levels of lipoprotein lipase (genomic DNA). The primer sequences are noted in S4 Table.

**Visualization of mitochondria**

The number of mitochondria and their distribution were determined using the MitoTracker Red CMXRos selective probe (Invitrogen catalog #M7512). The myotubes were incubated in a medium without FBS and containing 50 nM MitoTracker for 30 min at 37˚C. The medium was then replaced with a complete medium but without MitoTracker. Live cell images were acquired using the LEICA DFC450 Imaging System. All samples were analysed using the same settings. The quantifications of mitotracker fluorescent signal intensity were performed in a blinded manner with Image J Fiji software.

**Antibodies and immunoblotting studies**

Antibodies directed against MHC1 (BA-D5) and MHC2b (BF-F3) were purchased from the Developmental Studies Hybridoma Bank; antibodies directed against NDUFB8 (14794-1-AP, 1:1,000 dilution), UQRC2 (14742-1-AP, 1:1,000 dilution), COX4 (11242-1-AP, 1:1,000 dilution), ATP5A (14676-1-AP, 1:1,000 dilution), MFN1 (13798-1-AP, 1:1,000 dilution), DRP1 (12957-1-AP, 1:1,000 dilution) were all from Proteintech; antibodies directed against OPA1 (612606, 1:1,000 dilution) were from BD Biosciences; antibodies directed against cytochrome c (bs1089, 1:1,000 dilution) and α-tubulin (bs1699, 1:5,000 dilution) were from Bioworld;
antibodies directed against myoglobin (sc-25607, 1:1,000 dilution), MFN2 (sc-100560, 1:500 dilution) were from Santa Cruz; antibodies directed against FLCN (#3697, 1:1,000 dilution), p-AMPKα Thr172 (#2535, 1:1,000 dilution), p-ACC Ser79 (#11818, 1:1,000 dilution), ACC (#3676, 1:1,000 dilution), p-mTOR Ser2448 (#5536, 1:1,000 dilution), p-mTOR Ser2481 (#2974, 1:1,000 dilution), mTOR (#2983, 1:1,000 dilution), p-S6K (#2934, 1:1,000 dilution), S6K (#2708, 1:1,000 dilution), p-S6 (#4858, 1:1,000 dilution), S6 (#2317, 1:1,000 dilution), p-4EBP1 (#2855, 1:1,000 dilution) and 4EBP1 (#9644, 1:1,000 dilution) were from Cell Signaling Technology; antibody directed against β-Actin (AC026, 1:5,000 dilution) was from Abclonal; anti-PGC-1α (1,1,000 dilution) was developed in the laboratory of Daniel Kelly as previously described [50]; anti-FNIP1 was developed in the laboratory of Zhenji Gan with the help with Abcam (ab236547, 1:500 dilution); Western blotting studies were performed as previously described [47,48]. Blots were normalized to α-tubulin. The total protein concentration was measure by BCA assay using Pierce BCA Assay Kit Protocol (ThermoFischer Scientific). Equal total protein was loaded to each lane and the membranes were also stained with 0.1% Ponceau S.

LDH isoenzyme analysis and activity assay
LDH isoenzyme patterns were determined as previously described [28]. Briefly, mouse skeletal muscle were homogenized in a solution of 0.9% NaCl, 5 mM Tris-HCl, pH 7.4, and the lysates were centrifuged for 30 min at 15,000 × g to remove the cellular debris. 100 μg of protein/lane was loaded onto a 6% nondenaturing polyacrylamide gel. Following electrophoresis, the gel was placed in 10 ml of staining solution containing 0.1 M sodium lactate, 1.5 mM NAD, 0.1 M Tris-HCl (pH 8.6), 10 mM NaCl, 5 mM MgCl2, 0.03 mg/ml phenazinemethosulphate, and 0.25 mg/ml nitro blue tetrazolium. Protein extracted from mouse heart served as a positive control.

Cell culture
Primary muscle cells were isolated from gastrocnemius (GC) muscles of 4-week old male mice as previously described [25,40,47,51]. Briefly, GC muscles from both legs were removed. Minced tissue was digested in a collagenase/dispase/CaCl2 solution for 1.5 hours at 37˚C in a shaking bath. DMEM supplemented with 10% FBS (PPM) was added and samples were triturated gently before loading onto a Netwell filter (70 μm, BD). Cell suspension was pelleted at 1000 rpm for 5 minutes. Cells were then resuspended in PPM and plated on an uncoated plate for differential plating. Cell suspension (not-adherent) was centrifuged for 5 minutes at 1000 rpm and pellet was resuspended in Growth Medium (GM) (Ham’s F-10 medium supplemented with 20% FBS and 2.5 ng/ml bFGF). Cells were plated on collagen coated flasks for expansion. Cells were fed daily with GM. For differentiation, cells were washed with PBS and re-fed with 2% Horse-serum/DMEM differentiation medium and re-fed daily. Cells were induced to differentiation for 3 days prior to various experiments.

Statistical analyses
All mouse and cell studies were analyzed by Student’s t test when two groups were compared. One-way ANOVA coupled to a Fisher’s least significant difference (LSD) post-hoc test or two-way ANOVA coupled to Bonferroni post-hoc test were used when more than two groups were compared. Data represent the mean ± SD, with a statistically significant difference defined as a value of P < 0.05. All the numerical data were presented in S1 Data.
Supporting information

S1 Fig. Generation and characterization of muscle-specific 
Fnip1 transgenic mice. (A) The schematic depicts the 
Mck-Fnip1 construct used for Fnip1Tg transgene production. (B) RT-
qPCR analysis of Fnip1 mRNA levels in the entire gastrocnemius (GC) muscle from nontrans-
genic (NTG) and Fnip1Tg mice. n = 4 mice per group. (C) Representative immunoblot analysis 
of protein extracts prepared from white vastus lateralis (WV) muscles, heart (Ht) and liver of 
the indicated mice using FLAG and α-Tubulin (control) antibodies. n = 4 mice per group. (D) 
(Left) Pictures of NTG and Fnip1Tg mice at the age of 8 weeks. (Right) Representative soleus, 
GC and WV muscles from indicated mice. (E) Cross-section of GC muscle from 8-week-old 
amale NTG and Fnip1Tg mice stained for MHC immunofluorescence (IF). Representative 
images were shown. M (medial head of GC), MHC1 (green), and MHC2b (red). Scale bar: 
300 μm. (F) Quantification of IF data shown in (E). n = 3–4 mice per group. Values represent 
mean ± SD, *P < 0.05 vs. NTG controls.

(TIF)

S2 Fig. Generation and characterization of 
Fnip1 KO mice. (A) Schematic showing the Cas9 
system targeting exon 6 of the 
Fnip1 gene to generate Fnip1 knockout mice (Fnip1KO). (B) 
Detection of the Fnip1 mutation by PCR. Primers flanking the exon 6 of the Fnip1 gene gener-
ate PCR products as indicated. (C) Results of RT-qPCR analysis of Fnip1, Fnip2 and Flcn 
mRNA levels in entire GC muscles from indicated mice. n = 5 mice per group. (D) Immuno-
blot analysis of protein extracts prepared from WV muscles of the indicated mice using 
FNIP1, FLCN and α-Tubulin (control) antibodies. n = 4 mice per group. (E) Representative 
pictures showing WT and Fnip1KO mice skeletal muscle at the age of 8 weeks. Values represent 
mean ± SD, *P < 0.05 vs. WT controls.

(TIF)

S3 Fig. Analysis of genes regulated in 
Fnip1KO muscle. (A) Volcano plot showing fold 
changes versus P-values for the analyzed RNA-seq data generated from the entire GC muscle 
of 8-week-old male Fnip1KO mice compared to WT controls. Significantly up-regulated genes 
are represented by red dots, whereas down-regulated genes are represented by blue dots. (B) 
Gene ontology (GO) enrichment analysis of gene transcripts (top 3000) up-regulated in 
Fnip1KO muscle, with the top ten terms shown. (C) Heat-map of up-regulated mitochondrial 
complex genes in Fnip1KO muscles, color scheme for fold change is provided. (D) GO enrich-
ment analysis of 739 gene transcripts down-regulated in Fnip1KO muscle. (E) Heat maps 
depicting a subset of gene expression data, individual genes involved in the regulation of type I 
muscle fiber specification are shown to be regulated in the Fnip1KO as denoted by the color 
scheme (relative fold change compared to WT control shown to the right of each gene). (F) 
RNA-seq data of WT and Fnip1KO muscle indicate an increase expression of miR-208b and 
miR-499.

(TIF)

S4 Fig. Analysis of genes regulated in 
Fnip1TgKO muscle. (A) Volcano plot showing fold 
changes versus P-values for the analyzed RNA-seq data generated from the entire GC muscle 
of 8-week-old male Fnip1TgKO mice compared to WT controls. Significantly up-regulated 
genes are represented by red dots, whereas down-regulated genes are represented by blue dots. 
(B, C) GO enrichment analysis of gene transcripts up-regulated in Fnip1TgKO muscle. (D, E) 
GO enrichment analysis of gene transcripts down-regulated in Fnip1TgKO muscle.

(TIF)
S5 Fig. FNIP1-dependent muscle oxidative transformation. (A, C) Immunoblot analysis of entire GC muscle lysates for mice of the indicated genotype using the indicated antibodies. Ponceau red staining was also shown. n = 3 mice per group. (B) Mitochondrial respiration rates were determined from the plantaris part of the gastrocnemius/plantaris complex of the indicated genotypes using pyruvate or succinate as substrates. Pyruvate/malate (Py/M) or succinate/rotenone (Suc/Rot)-stimulated, ADP-dependent respiration and oligomycin-induced (Oligo) are shown. n = 4 mice per group. (D) (Top) Immunoblot analysis of WV muscle lysates for mice of the indicated genotype using the myoglobin antibody. (Bottom) Ponceau red staining was shown. n = 3 mice per group. (E) Quantification of LDH isoenzyme activity gel electrophoresis. Values represent the mean % (± SD) total LDH activity. n = 3 mice per group. Values represent mean ± SD, *P < 0.05 vs. WT controls, #P < 0.05 vs. Fnip1KO. (TIF)

S6 Fig. mTOR signaling-independent regulation by FNIP1. (A) Low power MHC immunofluorescence scan showing entire cross-section of the mid-belly GC muscle of WT, Fnip1KO and Fnip1tgKO mice at the age of 8 weeks. (M) medial; (L) lateral; (PL) plantaris. MHC1 (green), and MHC2b (red). Scale bar: 1000 μm. (B) Immunoblot analysis of WV muscle lysates for mice of the indicated genotype using the indicated antibodies. (C) Quantification of the p-S6K (Thr389)/S6K, p-S6 (Ser235/236)/S6 and p-4EBP1 (Thr37/46)/4EBP1 signal ratios were normalized (= 1.0) to the Fnip1KO. n = 3 mice per group. (TIF)

S7 Fig. FNIP1 regulates muscle mitochondrial oxidative programs through AMPK. (A) (Top) Immunoblot analysis of muscle lysates for mice of the indicated genotype using the cytochrome c antibody. (Bottom) Ponceau red staining was shown. n = 3 mice per group. (B-D) Primary skeletal muscle myoblasts were isolated from GC muscles of WT, Fnip1KO, or AMPKa1/a2f/f/Myf5-Cre (TKO) mice, and then induced to differentiation for 3 days. (B) (Top) Immunoblot analysis of myotube extracts using the COX4 antibody. (Bottom) Ponceau red staining was shown. (C) (Top) Myotubes were stained with MitoTracker Red CMXRos, (Bottom) Phase contrast microscopy images of myotubes were shown. Scale bars: 100 μm. (D) Quantification of mitotracker fluorescent signal intensity in (C). n = 3 independent experiments. Values represent mean ± SD, *P < 0.05 vs. WT controls, #P < 0.05 vs. Fnip1KO. (TIF)

S8 Fig. AMPK-independent regulation of muscle fiber type switching by FNIP1. Expression of myosin heavy chain (MHC) and representative slow/fast-twitch troponin genes (qRT-PCR) in soleus muscles from indicated mice. n = 4–6 mice per group. Values represent mean ± SD, *P < 0.05 vs. WT controls. (TIF)

S9 Fig. PGC-1α is indispensable for the FNIP1-mediated control of muscle mitochondrial oxidative program. (Top) Immunoblot analysis of entire GC muscle lysates for mice of the indicated genotype using the cytochrome c antibody. (Bottom) Ponceau red staining was shown. n = 3 mice per group. (TIF)

S1 Table. Body weight and muscle weight measurements. (DOCX)

S2 Table. FNIP1-dependent mitochondrial-related genes (455). (DOCX)
S3 Table. sgRNA for Fnip1 knockout mice generation.
(DOCX)

S4 Table. RT-PCR primers.
(DOCX)

S1 Data. Raw numerical data of all the figures.
(XLSX)

Author Contributions

Conceptualization: Liwei Xiao, Jing Liu, Zongchao Sun, Zhenji Gan.

Data curation: Liwei Xiao, Jing Liu, Zongchao Sun, Zhenji Gan.

Formal analysis: Liwei Xiao, Jing Liu, Zongchao Sun.

Funding acquisition: Tingting Fu, Zhenji Gan.

Investigation: Liwei Xiao, Jing Liu, Zongchao Sun, Yujing Yin, Yan Mao, Dengqiu Xu, Lin Liu, Zhisheng Xu, Qiqi Guo, Chenyun Ding, Wanping Sun, Likun Yang, Zheng Zhou, Danxia Zhou, Tingting Fu, Wenjing Zhou, Yuangang Zhu.

Resources: Xiao-Wei Chen, John Zhong Li, Shuai Chen, Xiaoduo Xie.

Supervision: Zhenji Gan.

Validation: Liwei Xiao, Jing Liu, Zongchao Sun.

Visualization: Liwei Xiao, Jing Liu, Zongchao Sun.

Writing – original draft: Liwei Xiao, Zhenji Gan.

Writing – review & editing: Liwei Xiao, Zongchao Sun, Zhenji Gan.

References

1. Lowell BB, Shulman GI. Mitochondrial dysfunction and type 2 diabetes. Science. 2005; 307(5708):384–7. Epub 2005/01/22. https://doi.org/10.1126/science.1104343 PMID: 15662004.

2. Muoio DM, Neufeld PD. Lipid-induced mitochondrial stress and insulin action in muscle. Cell metabolism. 2012; 15(5):595–605. Epub 2012/05/09. https://doi.org/10.1016/j.cmet.2012.04.010 PMID: 22560212; PubMed Central PMCID: PMC3348508.

3. Hesselink MK, Schrauwen-Hinderling V, Schrauwen P. Skeletal muscle mitochondria as a target to prevent or treat type 2 diabetes mellitus. Nat Rev Endocrinol. 2016; 12(11):633–45. Epub 2016/07/23. https://doi.org/10.1038/nrendo.2016.104 PMID: 27448057.

4. Gan Z, Fu T, Kelly DP, Vega RB. Skeletal muscle mitochondrial remodeling in exercise and diseases. Cell Res. 2018; 28(10):969–80. Epub 2018/08/16. https://doi.org/10.1038/s41422-018-0078-7 PMID: 30108290; PubMed Central PMCID: PMC6170448.

5. Egan B, Zierath JR. Exercise metabolism and the molecular regulation of skeletal muscle adaptation. Cell metabolism. 2013; 17(2):162–84. Epub 2013/02/12. https://doi.org/10.1016/j.cmet.2012.12.012 PMID: 23395166.

6. Holloszy JO, Coyle EF. Adaptations of skeletal muscle to endurance exercise and their metabolic consequences. J Appi Physiol Respir Environ Exerc Physiol. 1984; 56(4):831–8. Epub 1984/04/01. https://doi.org/10.1152/jappi.1984.56.4.831 PMID: 6373687.

7. Neufeld PD, Bamman MM, Muoio DM, Bouchard C, Cooper DM, Goodpaster BH, et al. Understanding the Cellular and Molecular Mechanisms of Physical Activity-Induced Health Benefits. Cell metabolism. 2015; 22(1):4–11. Epub 2015/06/16. https://doi.org/10.1016/j.cmet.2015.05.011 PMID: 26073496.

8. Yan Z, Okutsu M, Akhtar YN, Lira VA. Regulation of exercise-induced fiber type transformation, mitochondrial biogenesis, and angiogenesis in skeletal muscle. Journal of applied physiology (Bethesda, Md: 1985). 2011; 110(1):264–74. Epub 2010/10/30. https://doi.org/10.1152/jappphysiol.00993.2010 PMID: 21030673; PubMed Central PMCID: PMC3253006.
9. Zong H, Ren JM, Young LH, Pypaert M, Mu J, Birmbaum MJ, et al. AMP kinase is required for mitochondrial biogenesis in skeletal muscle in response to chronic energy deprivation. Proceedings of the National Academy of Sciences of the United States of America. 2002; 99(25):15983–7. Epub 2002/11/22. https://doi.org/10.1073/pnas.252625599 PMID: 12444247; PubMed Central PMCID: PMC138551.

10. Lee-Young RS, Griffee SR, Lynes SE, Bracy DP, Ayala JE, McGuinness OP, et al. Skeletal muscle AMP-activated protein kinase is essential for the metabolic response to exercise in vivo. The Journal of biological chemistry. 2009; 284(36):23925–34. Epub 2009/06/16. https://doi.org/10.1074/jbc.M109.021048 PMID: 19525228; PubMed Central PMCID: PMC2781986.

11. O’Neill HM, Maarbjerg SJ, Crane JD, Jeppesen J, Jorgensen SB, Schertzer JD, et al. AMP-activated protein kinase (AMPK) beta1beta2 muscle null mice reveal an essential role for AMPK in maintaining mitochondrial content and glucose uptake during exercise. The Proceedings of the National Academy of Sciences of the United States of America. 2011; 108(38):16092–7. Epub 2011/09/08. https://doi.org/10.1073/pnas.1105062108 PMID: 21896769; PubMed Central PMCID: PMC3179037.

12. Narkar VA, Downes M, Yu RT, Embler E, Wang YX, Banayo E, et al. AMPK and PPARdelta agonists are exercise mimetics. Cell. 2008; 134(3):405–15. Epub 2008/08/05. https://doi.org/10.1016/j.cell.2008.06.051 PMID: 18674809; PubMed Central PMCID: PMC2706130.

13. Garcia-Roves PM, Oser ME, Holmström MH, Zierath JR. Gain-of-function R225Q mutation in AMP-activated protein kinase gamma3 subunit increases mitochondrial biogenesis in glycolytic skeletal muscle. The Journal of biological chemistry. 2008; 283(51):35724–34. Epub 2008/10/08. https://doi.org/10.1074/jbc.M805078200 PMID: 18838377.

14. Handschin C, Spiegelman BM. Peroxisome proliferator-activated receptor gamma coactivator 1 coactivators: inducible regulators of energy metabolism in health and disease. The Journal of biological chemistry. 2008; 283(51):35724–34. Epub 2008/10/08. https://doi.org/10.1074/jbc.M805078200 PMID: 18838377.

15. Finck BN, Kelly DP. PGC-1 coactivators: inducible regulators of energy metabolism in health and disease. The Journal of clinical investigation. 2006; 116(3):615–22. Epub 2006/03/03. https://doi.org/10.1172/JCI27794 PMID: 16511594; PubMed Central PMCID: PMC1386111.

16. Jäger S, Handschin C, St-Pierre J, Spiegelman BM. AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha. Proceedings of the National Academy of Sciences of the United States of America. 2007; 104(29):12017–22. Epub 2007/07/05. https://doi.org/10.1073/pnas.0705070104 PMID: 17609368; PubMed Central PMCID: PMC1924552.

17. Canto C, Gerhart-Hines Z, Feige JN, Lagouge M, Noriega L, Milne JC, et al. AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature. 2009; 458(7241):1056–60. Epub 2009/03/06. https://doi.org/10.1038/nature07813 PMID: 19262508; PubMed Central PMCID: PMC3616311.

18. Baba M, Hong SB, Sharma N, Warren MB, Nickerson ML, Iwamatsu A, et al. Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling. Proceedings of the National Academy of Sciences of the United States of America. 2006; 103(42):15552–7. Epub 2006/10/10. https://doi.org/10.1073/pnas.0603781103 PMID: 17028174; PubMed Central PMCID: PMC1592464.

19. Park H, Staehling K, Tsang M, Appleby MW, Brunkow ME, Margineantu D, et al. Disruption of Fnip1 reveals a metabolic checkpoint controlling B lymphocyte development. Immunity. 2012; 36(5):769–81. Epub 2012/05/23. https://doi.org/10.1016/j.immuni.2012.02.019 PMID: 22608497; PubMed Central PMCID: PMC3631584.

20. Reyes NL, Banks GB, Tsang M, Margineantu D, Gu H, Dijukovic D, et al. Fnip1 regulates skeletal muscle fiber type specification, fatigue resistance, and susceptibility to muscular dystrophy. Proceedings of the National Academy of Sciences of the United States of America. 2015; 112(2):424–9. Epub 2014/12/31. https://doi.org/10.1073/pnas.1413021103 PMID: 25548157; PubMed Central PMCID: PMC4299192.

21. Hasumi H, Baba M, Hasumi Y, Lang M, Huang Y, Oh HF, et al. Folliculin-interacting proteins Fnip1 and Fnip2 play critical roles in kidney tumor suppression in cooperation with Fcn. Proceedings of the National Academy of Sciences of the United States of America. 2015; 112(13):E1624–31. Epub 2015/03/17. https://doi.org/10.1073/pnas.1419502112 PMID: 25775561; PubMed Central PMCID: PMC4386336.

22. Siggs OM, Stockenhuber A, Deobagkar-Lele M, Bull KR, Crockford TL, Kingston BL, et al. Mutation of Fnip1 is associated with B-cell deficiency, cardiomyopathy, and elevated AMPK activity. Proceedings of the National Academy of Sciences of the United States of America. 2016; 113(26):E3706–15. Epub 2016/06/16. https://doi.org/10.1073/pnas.1607592113 PMID: 27303042; PubMed Central PMCID: PMC4932993.

23. Ramirez JA, Iwata T, Park H, Tsang M, Kang J, Cui K, et al. Folliculin Interacting Protein 1 Maintains Metabolic Homeostasis during B Cell Development by Modulating AMPK, mTORC1, and TFE3. J
FNIP1 coordinates mitochondrial function muscle fiber type
40. Gan Z, Rumsey J, Hazen BC, Lai L, Leone TC, Vega RB, et al. Nuclear receptor/microRNA circuitry links muscle fiber type to energy metabolism. The Journal of clinical investigation. 2013; 123(6):2564–75. Epub 2013/05/17. https://doi.org/10.1172/JCI67652 PMID: 2367496; PubMed Central PMCID: PMC3668841.

41. Yokoyama S, Ohno Y, Egawa T, Yasuhara K, Nakai A, Sugira T, et al. Heat shock transcription factor 1-associated expression of slow myosin heavy chain in mouse soleus muscle in response to unloading with or without reloading. Acta physiologica (Oxford, England). 2016; 217(4):325–37. Epub 2016/04/17. https://doi.org/10.1111/apha.12692 PMID: 27084024.

42. Zhang CS, Jiang B, Li M, Zhu M, Peng Y, Zhang YL, et al. The lysosomal v-ATPase-Ragulator complex is a common activator for AMPK and mTORC1, acting as a switch between catabolism and anabolism. Cell metabolism. 2014; 20(3):526–40. Epub 2014/07/09. https://doi.org/10.1016/j.cmet.2014.06.014 PMID: 25002183.

43. Meng J, Ferguson SM. GATOR1-dependent recruitment of FLCN-FNIP to lysosomes coordinates Rag GTPase heterodimer nucleotide status in response to amino acids. The Journal of cell biology. 2018; 217(8):2765–76. Epub 2018/06/01. https://doi.org/10.1083/jcb.201712177 PMID: 29848618; PubMed Central PMCID: PMC6080935.

44. Woodford MR, Dunn DM, Blanden AR, Capriotti D, Loiselle D, Prodromou C, et al. The FNIP co-chaperones decelerate the Hsp90 chaperone cycle and enhance drug binding. Nat Commun. 2016; 7:12037. Epub 2016/06/30. https://doi.org/10.1038/ncomms12037 PMID: 27933360; PubMed Central PMCID: PMC4931344.

45. Manford AG, Rodriguez-Perez F, Shiht KY, Shi Z, Berdan CA, Choe M, et al. A Cellular Mechanism to Detect and Alleviate Reductive Stress. Cell. 2020; 183(1):46–61.e21. Epub 2020/09/18. https://doi.org/10.1016/j.cell.2020.08.034 PMID: 32941802.

46. Chen Q, Xie B, Zhu S, Rong P, Sheng Y, Ducommun S, et al. A Tbc1d1 (Ser231Ala)-knockin mutation partially impairs AICAR- but not exercise-induced muscle glucose uptake in mice. Diabetologia. 2017; 60(2):336–45. Epub 2016/11/09. https://doi.org/10.1007/s00125-016-4151-9 PMID: 27826658.

47. Fu T, Xu Z, Liu L, Guo Q, Wu H, Liang X, et al. Mitophagy Directs Muscle-Adipose Crosstalk to Alleviate Dietary Obesity. Cell Rep. 2018; 23(5):1357–72. Epub 2018/05/03. https://doi.org/10.1016/j.celrep.2018.03.127 PMID: 29719625.

48. Liu L, Cai J, Wang H, Liang X, Zhou Q, Ding C, et al. Coupling of COPII vesicle trafficking to nutrient availability by the IRE1α-XBP1s axis. Proceedings of the National Academy of Sciences of the United States of America. 2019; 116(24):11776–85. Epub 2019/05/28. https://doi.org/10.1073/pnas.1814480116 PMID: 31123148; PubMed Central PMCID: PMC6575159.

49. Liu L, Ding C, Fu T, Feng Z, Lee JF, Xiao L, et al. Histone methyltransferase MLL4 controls myofiber identity and muscle performance through MEF2 interaction. The Journal of clinical investigation. 2020. Epub 2020/06/17. https://doi.org/10.1172/JCI136155 PMID: 32544095.

50. Leone TC, Lehman JJ, Finck BN, Schaeffer PJ, Wende AR, Boudina S, et al. PGC-1alpha deficiency causes multi-system energy metabolic derangements: muscle dysfunction, abnormal weight control and hepatic steatosis. PLoS Biol. 2005; 3(4):e101. Epub 2005/03/12. https://doi.org/10.1371/journal.pbio.0030101 PMID: 15760270; PubMed Central PMCID: PMC1064854.

51. Rand TA, Blau HM. Primary mouse myoblast purification, characterization, and transplantation for cell-mediated gene therapy. The Journal of cell biology. 1994; 125(6):1275–87. Epub 1994/06/01. https://doi.org/10.1083/jcb.125.6.1275 PMID: 8207057; PubMed Central PMCID: PMC2290930.